Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 2/20 | 0.63 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.58 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | IGF1R | P08069 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1773799 | 0.95 | ESR2 (0.65) | NR1H2ESR2GPR119MAPK1HDAC1 | |
| SCHEMBL1790023 | 0.93 | ESR2 (0.54) | NR1H2ESR2GPR119NPC1RAB9A | |
| SCHEMBL1285596 | 0.85 | NR1H2 (0.69) | NR1H2ESR2GPR119MAPK1HDAC1 | |
| SCHEMBL29407557 | 0.85 | NR1H2 (0.69) | NR1H2ESR2GPR119MAPK1HDAC1 | |
| SCHEMBL12376466 | 0.85 | NR1H2 (0.69) | NR1H2ESR2MAPK1HDAC1TMEM97 | |
| SCHEMBL22981583 | 0.84 | NR1H2 (0.67) | NR1H2ESR2MAPK1HDAC1TMEM97 | |
| SCHEMBL1286143 | 0.84 | NR1H2 (0.67) | NR1H2ESR2MAPK1HDAC1TMEM97 | |
| SCHEMBL4015963 | 0.84 | NR1H2 (0.67) | NR1H2ESR2MAPK1HDAC1TMEM97 | |
| SCHEMBL29388691 | 0.84 | NR1H2 (0.67) | NR1H2ESR2MAPK1HDAC1TMEM97 | |
| SCHEMBL29421745 | 0.84 | NR1H2 (0.67) | NR1H2ESR2MAPK1HDAC1TMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150158842-A1 | PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-06-11 | — | — | US | disclosed |
| US-20150158842-A1 | PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-06-11 | — | — | US | disclosed |
| US-20150158842-A1 | PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-06-11 | — | — | US | disclosed |
| US-9045459-B2 | Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-06-02 | — | — | US | disclosed |
| US-9045459-B2 | Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-06-02 | — | — | US | disclosed |
| US-9045459-B2 | Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-06-02 | — | — | US | disclosed |
| US-20120088790-A1 | PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT GMBH & CO. KG (DE) | 2012-04-12 | — | — | US | disclosed |
| US-20120088790-A1 | PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT GMBH & CO. KG (DE) | 2012-04-12 | — | — | US | disclosed |
| US-20120088790-A1 | PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT GMBH & CO. KG (DE) | 2012-04-12 | — | — | US | disclosed |
| WO-2012020134-A1 | PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT GMBH & CO. KG (DE) | 2012-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158842-A1 | PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | KCNT1, CEPT1, PIGT | NR1H2 2253/4885ESR2 4537/4885GPR119 936/4885 |
| US-20120088790-A1 | PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | KCNT1, CEPT1, PIGT | NR1H2 2253/4885ESR2 4537/4885GPR119 936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.